Icecure Medical (Icecure Medical) FCF Margin % : -217.13% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Icecure Medical FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Icecure Medical's Free Cash Flow for the three months ended in Dec. 2023 was $-2.73 Mil. Icecure Medical's Revenue for the three months ended in Dec. 2023 was $1.26 Mil. Therefore, Icecure Medical's FCF Margin % for the quarter that ended in Dec. 2023 was -217.13%.

As of today, Icecure Medical's current FCF Yield % is -24.30%.

The historical rank and industry rank for Icecure Medical's FCF Margin % or its related term are showing as below:

ICCM' s FCF Margin % Range Over the Past 10 Years
Min: -504.64 Med: -351.16 Max: -101.16
Current: -402.63

During the past 11 years, the highest FCF Margin % of Icecure Medical was -101.16%. The lowest was -504.64%. And the median was -351.16%.

ICCM's FCF Margin % is ranked worse than
88.24% of 825 companies
in the Medical Devices & Instruments industry
Industry Median: -7.14 vs ICCM: -402.63

Icecure Medical FCF Margin % Historical Data

The historical data trend for Icecure Medical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icecure Medical FCF Margin % Chart

Icecure Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-111.22

-101.16

-317.50

-492.16

-402.63

Icecure Medical Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-450.27	-448.87	-394.34	-1,037.92	-217.13

Competitive Comparison of Icecure Medical's FCF Margin %

For the Medical Devices subindustry, Icecure Medical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Icecure Medical's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Icecure Medical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Icecure Medical's FCF Margin % falls into.

Icecure Medical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Icecure Medical's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-13.001	/	3.229
	=	-402.63 %

Icecure Medical's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2.725	/	1.255
	=	-217.13 %

Icecure Medical FCF Margin % Related Terms

Thank you for viewing the detailed overview of Icecure Medical's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Icecure Medical (Icecure Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Icecure Medical Ltd (NAS:ICCM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Haeshel Street, Southern Industrial Park, PO Box 3163, Caesarea, ISR, 3079504

Website

https://www.icecure-medical.com

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.